What You Need to Know About Continuous Glucose Monitors

Continuous Glucose Monitors (CGMs) have fundamentally reshaped diabetes care by providing patients with immediate insight into their glucose dynamics. Unlike traditional blood glucose meters that offer only point-in-time readings, CGMs measure glucose levels in the interstitial fluid every few minutes, generating a continuous data stream that reveals trends, patterns, and real-time fluctuations. For individuals managing type 1 diabetes, type 2 diabetes, or gestational diabetes, this technology supports more precise insulin dosing, dietary adjustments, and lifestyle decisions. This article provides a comprehensive examination of CGM technology, including how these devices work, their clinical benefits, practical limitations, and how to choose the right system for your needs.

What Is a Continuous Glucose Monitor?

A continuous glucose monitor is a medical device that automatically tracks glucose levels throughout the day and night without requiring routine fingerstick calibration on many modern systems. The core concept dates back to the early 2000s when the first real-time CGM received FDA approval. Since then, the technology has undergone rapid evolution: sensors have become smaller, more accurate, and more comfortable to wear; transmitters have become wireless and smartphone-compatible; and algorithms now generate actionable insights such as predicted hypoglycemia alarms.

The fundamental advantage of a CGM over conventional self-monitoring of blood glucose (SMBG) is that it eliminates gaps in data. While a fingerstick tells you exactly what your blood glucose is at one moment, a CGM shows you not only the current value but also the direction and speed of change. This ability to see glucose trajectories empowers users to intervene preemptively—for example, consuming a snack before a low becomes severe or adjusting insulin boluses before a high spikes.

CGMs are now integrated into automated insulin delivery (AID) systems, sometimes called hybrid closed-loop or “artificial pancreas” systems, which automatically adjust insulin delivery based on CGM readings. This integration represents one of the most significant advances in diabetes management in the last decade.

How Do CGMs Work?

All CGMs share a common architecture composed of three essential components: a subcutaneous sensor, a transmitter, and a display device. The sensor is inserted just under the skin—typically on the abdomen, upper arm, or thigh—using an applicator that places a tiny, flexible filament into the interstitial fluid. Glucose in the interstitial fluid reacts with glucose oxidase on the sensor filament, generating an electrical current proportional to the glucose concentration. This current is measured every one to five minutes, depending on the device design.

Sensor Technology

Modern sensors are designed to be worn for 7 to 14 days (some models last up to 15 days). The filament is ultra-thin (often less than 1 mm in diameter) and made of biocompatible materials to minimize tissue reaction. The sensor’s lifetime is limited by enzyme degradation and fibrosis around the insertion site. Some systems allow sensor reinsertion by the user, while others are single-use. Accuracy is quantified using the Mean Absolute Relative Difference (MARD). A lower MARD indicates better performance; for example, many current-generation sensors achieve MARD values below 10%, which is considered highly acceptable for clinical decision-making.

Transmitter and Connectivity

The transmitter is physically attached to the sensor. In some systems, the transmitter is reusable and can be paired with multiple sensors over several months. In others, the transmitter is integrated into the sensor and discarded with it. The transmitter wirelessly transmits glucose data via Bluetooth or a proprietary radio frequency to a receiver, a dedicated reader, or directly to a smartphone. Many CGMs now support cloud connectivity, allowing caregivers or healthcare providers to view data remotely. The Dexcom G7 and Abbott FreeStyle Libre 3, for example, send data directly to a smartphone app, eliminating the need for a separate reader.

Display and Alerts

The display device—whether a dedicated receiver, smartphone, or smartwatch—shows the current glucose reading, a trend arrow indicating direction of change, and often a glucose graph showing the last several hours. Alarm thresholds can be set for low (hypoglycemia) and high (hyperglycemia) glucose levels. Some systems also include predictive alerts that warn when glucose is projected to cross a threshold within the next 20 to 30 minutes. These alerts are lifesaving: studies have shown that CGM-based alarms reduce the duration and severity of hypoglycemic events, especially during sleep.

Benefits of Using CGMs

The clinical evidence supporting CGM use is robust and spans multiple patient populations. Benefits extend beyond simple convenience to meaningful improvements in glycemic control, quality of life, and reduction of acute complications.

Real-time Glucose Monitoring and Immediate Adjustments

Users receive continuous updates, typically every one to five minutes, and can see the effect of food, exercise, stress, medication, and illness almost instantly. This feedback loop is powerful: a user can observe that a certain meal causes a delayed glucose spike and adjust their carbohydrate count or insulin timing accordingly. For people using multiple daily injections (MDI) or insulin pumps, the ability to detect postprandial hyperglycemia early allows for corrective boluses before values climb too high.

Trend Analysis and Pattern Recognition

CGMs store hundreds of data points each day, enabling users and clinicians to identify trends over days, weeks, or months. Standard reports—such as the ambulatory glucose profile (AGP) and time-in-range (TIR)—provide summaries of glucose exposure. The widely accepted target for TIR is >70% of readings between 70 and 180 mg/dL, with <4% below 70 mg/dL and <1% below 54 mg/dL. Studies have linked higher TIR with lower risk of diabetes complications, making this metric a key endpoint in clinical research.

Reduction of Fingerstick Burden

While many CGMs still require occasional calibration (especially older models), newer systems are factory-calibrated and do not require routine fingersticks. The FreeStyle Libre 2 and Libre 3, for example, are factory-calibrated and only need a fingerstick if symptoms do not match the sensor reading or during the first day of wear. This reduction in painful, inconvenient testing improves adherence and allows for more frequent monitoring, particularly in children and individuals with needle phobia.

Alerts and Alarms

Hypoglycemia unawareness—a condition where a person does not feel the onset of low blood glucose—is a dangerous complication of diabetes. CGMs with customizable alarms provide a safety net, waking users during nocturnal hypoglycemia or alerting them during exercise. Predictive alarms are particularly valuable: by sounding an alert when glucose is projected to fall below a threshold within 20 minutes, users can pre-emptively consume carbohydrates to avoid a full hypoglycemic episode. This feature has been shown to significantly reduce severe hypoglycemic events in both type 1 and type 2 diabetes.

Who Can Benefit from CGMs?

CGM use is expanding beyond its original indication for type 1 diabetes. Current guidelines from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommend CGM for anyone with diabetes who is on intensive insulin therapy (multiple daily injections or pump therapy) and for those who experience problematic hypoglycemia. Emerging evidence supports benefits in broader populations.

Type 1 Diabetes

For individuals with type 1 diabetes, CGM is considered a standard of care. Clinical trials such as the DIAMOND and GOLD studies demonstrated that CGM use leads to clinically significant reductions in HbA1c and hypoglycemia compared to fingerstick monitoring alone. CGM also enables the use of automated insulin delivery systems, which can further improve outcomes by automating basal insulin adjustments.

Type 2 Diabetes Requiring Insulin

People with type 2 diabetes who use insulin—especially those on multiple daily injections—also gain substantial benefit. The MOBILE study published in 2021 showed that CGM use in type 2 diabetes led to a 0.3% reduction in HbA1c and a 0.6% improvement in time in range compared to SMBG. For those on less intensive therapy, CGM may still be valuable for education and lifestyle modification, though cost and insurance coverage remain barriers.

Gestational Diabetes and Pregnancy

Managing diabetes during pregnancy demands tight glucose control to reduce risks for both mother and baby. CGM provides the continuous data necessary to fine-tune insulin therapy and diet, particularly during the second and third trimesters when insulin resistance changes rapidly. Studies have shown that CGM use in pregnant women with type 1 diabetes reduces neonatal hypoglycemia and macrosomia. Use in gestational diabetes (GDM) is also growing, with some research indicating improved outcomes compared to standard monitoring.

Pediatrics

Children with diabetes, especially young children, often face challenges with fingerstick compliance. CGM reduces the number of painful tests and allows parents to monitor their child's glucose remotely via smartphone. Many CGMs now have age indications down to age 2. The ability to set low glucose alarms gives parents peace of mind during sleep and school hours. CGM use in pediatric populations has been linked to better glycemic control and reduced parental distress.

Limitations and Considerations

Despite their many advantages, CGMs have limitations that users should understand. Some limitations are technical, while others are practical or financial.

Accuracy and Calibration

While modern sensors are highly accurate, accuracy can still be compromised during periods of rapid glucose change—for example, after a meal or during intense exercise—due to the physiological lag between interstitial fluid and blood glucose. This lag is typically 5 to 15 minutes. Most systems incorporate algorithms to compensate, but it is important for users to confirm with a fingerstick if symptoms do not match the sensor reading. Older systems require regular calibration (usually twice daily) with a traditional blood glucose meter to maintain accuracy. Newer factory-calibrated sensors eliminate this step, improving user experience.

Cost and Insurance Coverage

CGMs are significantly more expensive than blood glucose test strips. Out-of-pocket costs can be several hundred dollars per month without insurance. While Medicare and many private insurers cover CGMs for people with type 1 diabetes and those with type 2 diabetes using intensive insulin therapy, coverage varies widely for other populations. Prior authorization may be required, and some policies require documented frequent blood glucose monitoring or recent hypoglycemic events. Checking with your insurance provider before purchasing is essential. The FDA maintains a list of approved CGM systems and their indications, which can help guide conversations with insurers.

Skin Irritation and Adhesion Issues

The adhesive used to secure the sensor to the skin can cause irritation, redness, itching, or blistering in some users. This is especially common in warmer climates or with extended wear. Users with sensitive skin may need to use barrier wipes or hypoallergenic tapes. Adhesion can also fail during swimming, bathing, or excessive sweating, leading to premature sensor loss. Manufacturers have improved adhesives over time, but this remains a common complaint in user forums.

Interference with Certain Medications

Some CGM systems are known to be affected by certain medications or medical conditions. For example, certain sensors are sensitive to high doses of acetaminophen (Tylenol) and may report falsely high glucose readings. Ascorbic acid (vitamin C) and salicylic acid can also interfere. Users should review the product labeling for known interferences. Newer sensors, such as the Dexcom G7, have reformulated their electrodes to reduce these interactions, but caution is still warranted.

Data Overload and Psychological Burden

Having constant access to glucose data can be both a blessing and a burden. Some users experience “alarm fatigue,” tuning out frequent alerts or feeling anxious about every small fluctuation. Others may become overly focused on achieving perfect numbers, leading to distress and disordered eating. Healthcare providers often recommend taking breaks from CGM and using the device as a tool rather than a perfectionist scorecard. Cognitive behavioral therapy and diabetes education can help users develop a healthy relationship with the data.

Choosing the Right CGM

Several CGM systems are available in the United States and globally. The three leading manufacturers—Dexcom, Abbott, and Medtronic—each offer distinct features. The table below summarizes key differences, but users should consult current product specifications and speak with their healthcare provider.

Feature	Dexcom G7	Abbott FreeStyle Libre 3	Medtronic Guardian 4
Sensor wear duration	10 days	14 days	7 days
Factory calibrated	Yes	Yes	Yes (no fingersticks required)
Smartphone app	Yes (dedicated)	Yes (LibreLink)	Yes (connected to pump or phone)
Real-time sharing	Yes (up to 10 followers)	Yes (LibreLinkUp)	Yes (CareLink)
Integration with insulin pumps	Yes (t:slim X2, Omnipod 5)	Limited (Omnipod 5)	Yes (MiniMed pumps)
Alarm types	Urgent low, high, predictive	Urgent low, high, predictive	All including predictive low
MARD (accuracy)	~9%	~8%	~10%

Consider Your Treatment Regimen

If you use an insulin pump, compatibility with your pump is critical. Dexcom is the most widely integrated CGM, working with Tandem t:slim X2, Omnipod 5, and others. Abbott’s FreeStyle Libre 3 is only recently integrated with Omnipod 5. Medtronic’s Guardian 4 pairs exclusively with Medtronic pumps. For those on multiple daily injections, any system that provides a smartphone app and remote sharing will work well.

Evaluate Sensor Wear and Insertion

Some users prefer longer wear duration to reduce insertion frequency. The FreeStyle Libre 3 lasts 14 days, while Dexcom G7 lasts 10. Insertion mechanisms vary: Libre uses a one-button applicator that is relatively painless; Dexcom G7 also uses an easy applicator. Medtronic’s Guardian 4 may require an inserter that some find more intimidating. Try watching insertion videos or asking your diabetes educator for a sample if available.

Review Cost and Insurance

Pricing structures differ. Abbott often offers a discount for uninsured users through its Libre cash-pay program. Dexcom has a patient assistance program for those who qualify. Medtronic often bundles CGM with pump purchases. Check your insurance formulary and any prior authorization requirements. The American Diabetes Association provides resources on navigating insurance coverage for diabetes devices.

Future Directions in CGM Technology

The CGM field is advancing rapidly. Implantable sensors—such as the Eversense system, which is inserted subcutaneously and lasts up to 180 days—offer an alternative for users who want to avoid frequent sensor changes. Integration with smartwatches (Apple Watch, Garmin) is becoming standard, allowing glanceable glucose readings without pulling out a phone. Multi-sensor devices that combine glucose monitoring with ketone measurement are being developed. Closed-loop systems (the so-called “artificial pancreas”) are now available for people with type 1 diabetes and combine CGM with an insulin pump and a control algorithm to automate insulin delivery.

The next frontier includes connecting CGM data to other health metrics, such as heart rate, activity, and sleep, to provide a comprehensive picture of metabolic health. Several companies are exploring non-invasive optical sensors (e.g., using Raman spectroscopy or infrared light) that would eliminate the need for a subcutaneous sensor. While these are still in early clinical trials, the goal of a painless, calibration-free, wearable glucose monitor for both diabetic and prediabetic populations remains active research area.

Conclusion

Continuous glucose monitors have moved from a niche technology to a cornerstone of modern diabetes management. Their ability to deliver real-time data, trends, and alerts empowers users to make proactive decisions, reducing both short-term complications (hypoglycemia) and long-term risks (hyperglycemia-related complications). While cost, insurance hurdles, and occasional accuracy concerns persist, ongoing improvements in sensor design, factory calibration, and integration with insulin pumps are addressing many of these issues. By understanding how CGMs work, who benefits most, and how to select the right system, individuals with diabetes can harness this tool to achieve better glycemic outcomes and an improved quality of life. As always, consult a healthcare professional before starting any new diabetes technology, and reference authoritative sources such as the FDA and ADA Standards of Care for up-to-date clinical recommendations.